Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells

Leukemia

Volumn 11, Issue 2, 1997, Pages 253-257

  Huang, Y ^a   Ibrado, A M ^a   Reed, J C ^b   Bullock, G ^a   Ray, S ^a   Tang, C ^a   Bhalla, K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Bcl 2; Bcl x(L); MRP; P glycoprotein; Taxol

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MYC PROTEIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DNA TRANSFECTION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0031045308     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400557     Document Type: Article

References (14)

1. Gottesman MM. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53: 747-754.
2. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215-2222.
3. Scheffer CL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Piendo HM, Meijer CJLM, Clevers HC, Sheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nature Med 1995; 1: 578-582.
4. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-5910.
5. Dive C, Evans CA, Whetton AD. Induction of apoptosis - new targets for cancer chemotherapy. Semin Cancer Biol 1992; 3: 417-427.
6. Nunez G, Clarke MF. The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 1994; 4: 399-400.
7. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
8. Miyashita T, Reed JC. BCL-2 oncoprotein blocks chemotherapy-induced apoptosis in human leukemia cell line. Blood 1993; 81: 151-157.
9. L by cytotoxic drug exposure confers resistance to ionizing radiationinduced internucleosomal DNA fragmentation. Cell Growth Diff 1995; 6: 363-370.
10. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-4478.
11. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-1158.
12. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1995; 266: 807-810.
13. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of p26 BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994; 8: 1960-1969.
14. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-1256.